04:52 AM EST, 11/21/2024 (MT Newswires) -- Zai Lab ( ZLAB ) and Pfizer (PFE) said Thursday they are collaborating on the commercialization of XACDURO in mainland China.

The companies said Pfizer's affiliates will exclusively handle commercialization activities for the drug approved for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex.

The partnership for the imported product runs through November 2028, with options for early termination or extension.

Price: 25.80, Change: -0.43, Percent Change: -1.64